In a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $109.00. The company’s shares closed last Thursday at $44.20.
According to TipRanks.com, Hong ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.7% and a 27.2% success rate. Hong covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, ACADIA Pharmaceuticals, and Aldeyra Therapeutics.
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $87.57, which is an 86.9% upside from current levels. In a report issued on March 29, BTIG also maintained a Buy rating on the stock with a $62.00 price target.
The company has a one-year high of $74.10 and a one-year low of $19.38. Currently, Axsome Therapeutics has an average volume of 710.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Goldman Sachs Maintains Their Buy Rating on Bank of Queensland Limited (BKQNF)
- fuboTV: What Does the Subcription Price Hike Mean for the Stock?
- Cassava Stock: Despite Overhangs, the Risk-Reward Looks Appealing, Says Analyst
- RBC Capital Thinks Canfor’s Stock is Going to Recover
- RBC Capital Keeps Their Buy Rating on Interfor (IFSPF)